Halozyme Therapeutics traded at $44.00 this Thursday June 30th, decreasing $1.28 or 2.83 percent since the previous trading session. Looking back, over the last four weeks, Halozyme Therapeutics lost 4.31 percent. Over the last 12 months, its price fell by 5.09 percent. Looking ahead, we forecast Halozyme Therapeutics to be priced at 45.64 by the end of this quarter and at 42.05 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.09 -0.13 -0.91% -43.12%
Agios Pharmaceuticals 22.17 -0.21 -0.94% -60.71%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Amgen 243.30 -2.13 -0.87% -1.46%
Amarin 1.49 -0.33 -18.13% -66.59%
Aptinyx Inc 0.56 0.002 0.38% -80.56%
Baxter International 64.23 -1.58 -2.40% -21.16%
Cara Therapeutics 9.13 -0.47 -4.90% -36.82%
Cytokinetics 39.29 -9.45 -19.39% 87.27%
DBV Technologies 2.55 0.13 5.37% -55.18%
Esperion Therapeutics 6.36 -0.31 -4.65% -70.24%
Halozyme Therapeutics 44.00 -1.28 -2.83% -5.09%
Intercept Pharmaceuticals 13.81 0.14 1.02% -32.54%
Immunogen 4.50 0.14 3.21% -31.71%
Ionis Pharmaceuticals 37.02 -0.54 -1.44% -7.57%
Intra Cellular Therapies 57.08 -1.23 -2.11% 34.34%
Jazz Pharmaceuticals 156.01 -0.35 -0.22% -13.89%
Eli Lilly 324.23 1.23 0.38% 40.28%
MannKind 3.81 0.01 0.26% -30.47%
Minerva Neurosciences 3.31 -0.11 -3.22% 41.45%
Nektar Therapeutics 3.80 -0.16 -4.04% -78.31%
Pfizer 52.43 1.49 2.93% 32.53%
Peregrine Pharmaceuticals 15.26 0.09 0.59% -42.55%
Rigel Pharmaceuticals 1.13 0.10 9.71% -74.89%
United Therapeutics 235.64 -2.65 -1.11% 27.60%
Vanda Pharmaceuticals 10.90 0.05 0.46% -48.75%
Intrexon 1.34 -0.02 -1.47% -79.54%

Indexes Price Day Year
USND 11029 -149.16 -1.33% -24.06%
US2000 1708 -11.38 -0.66% -26.68%

Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.